Literature DB >> 30697136

Ceftaroline Plus Daptomycin for Refractory Methicillin- Resistant Staphylococcus aureus Bacteremia in a Child.

Alan M Hall, Sean M McTigue.   

Abstract

Persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia can be difficult to treat, with growing adult literature supporting the combination of ceftaroline and daptomycin for these patients. Here, we report a pediatric patient with persistent MRSA bacteremia with associated cellulitis, fasciitis, myositis, and a deep venous thrombosis causing septic pulmonary emboli. After being unable to clear the bacteremia on vancomycin and then daptomycin monotherapy, the bacteremia cleared quickly with rapid clinical improvement after the addition of ceftaroline to daptomycin. In support of this case, we also review the adult literature supporting treatment with this combination of antibiotics.

Entities:  

Keywords:  antibacterial agents; bacteremia; ceftaroline; child; daptomycin; methicillin-resistant Staphylococcus aureus; staphylococcal infections

Year:  2018        PMID: 30697136      PMCID: PMC6336175          DOI: 10.5863/1551-6776-23.6.490

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  14 in total

Review 1.  Ceftaroline: a new cephalosporin with activity against resistant gram-positive pathogens.

Authors:  Molly E Steed; Michael J Rybak
Journal:  Pharmacotherapy       Date:  2010-04       Impact factor: 4.705

2.  Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy.

Authors:  Tony T Ho; Jose Cadena; Lindsey M Childs; Miguel Gonzalez-Velez; James S Lewis
Journal:  J Antimicrob Chemother       Date:  2012-02-06       Impact factor: 5.790

3.  Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding.

Authors:  Abhay Dhand; Arnold S Bayer; Joseph Pogliano; Soo-Jin Yang; Michael Bolaris; Victor Nizet; Guiquing Wang; George Sakoulas
Journal:  Clin Infect Dis       Date:  2011-07-15       Impact factor: 9.079

4.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.

Authors:  Catherine Liu; Arnold Bayer; Sara E Cosgrove; Robert S Daum; Scott K Fridkin; Rachel J Gorwitz; Sheldon L Kaplan; Adolf W Karchmer; Donald P Levine; Barbara E Murray; Michael J Rybak; David A Talan; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2011-01-04       Impact factor: 9.079

5.  Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.

Authors:  Brian J Werth; George Sakoulas; Warren E Rose; Joseph Pogliano; Ryan Tewhey; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2012-10-15       Impact factor: 5.191

6.  β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives.

Authors:  Shrenik Mehta; Christopher Singh; Konrad B Plata; Palas K Chanda; Arundhati Paul; Sarah Riosa; Roberto R Rosato; Adriana E Rosato
Journal:  Antimicrob Agents Chemother       Date:  2012-09-17       Impact factor: 5.191

7.  Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline.

Authors:  George Sakoulas; Pamela A Moise; Anthony M Casapao; Poochit Nonejuie; Joshua Olson; Cheryl Y M Okumura; Michael J Rybak; Ravina Kullar; Abhay Dhand; Warren E Rose; Debra A Goff; Adam M Bressler; Yuman Lee; Joseph Pogliano; Scott Johns; Glenn W Kaatz; John R Ebright; Victor Nizet
Journal:  Clin Ther       Date:  2014-07-10       Impact factor: 3.393

8.  Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity.

Authors:  Warren E Rose; Lucas T Schulz; David Andes; Rob Striker; Andrew D Berti; Paul R Hutson; Sanjay K Shukla
Journal:  Antimicrob Agents Chemother       Date:  2012-08-06       Impact factor: 5.191

9.  Daptomycin therapy for invasive Gram-positive bacterial infections in children.

Authors:  Monica I Ardura; Asunción Mejías; Kathy S Katz; Paula Revell; George H McCracken; Pablo J Sánchez
Journal:  Pediatr Infect Dis J       Date:  2007-12       Impact factor: 2.129

10.  Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.

Authors:  Brian J Werth; Katie E Barber; Cortney E Ireland; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2014-03-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.